Snapshot from Aug 01, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Unicycive FDA CRL Investigation
Regulatory Securities Investigation

Unicycive FDA CRL Investigation

Analysis based on 13 articles · First reported Jun 30, 2026 · Last updated Jul 15, 2026

Sentiment
-30
Attention
2
Articles
13
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

Unicycive Therapeutics' stock price declined after the FDA's second Complete Response Letter, indicating ongoing regulatory hurdles. The investigation by Block & Leviton may lead to further legal costs and reputational damage for the company.

Pharmaceuticals Legal Services
Event Summary

Block & Leviton is investigating Unicycive Therapeutics for potential securities law violations after the FDA issued a second Complete Response Letter for its OLC New Drug Application on June 30, 2026, citing the same third-party manufacturing deficiencies as in June 2025. Unicycive's stock price declined following the announcement. The investigation focuses on whether the company made false or misleading statements or failed to disclose material information about the FDA review.

Key Actions
98 United States — Food and Drug Administration issued Complete Response Letter Unicycive Therapeutics
90 Unicycive Therapeutics announced FDA letter
80 Unicycive Therapeutics resubmitted NDA United States — Food and Drug Administration
70 Block & Leviton investigating securities law violations Unicycive Therapeutics
50 Unicycive Therapeutics held Type A meeting United States — Food and Drug Administration
Entities Involved
stock
Unicycive Therapeutics
Unicycive Therapeutics is the subject of a securities investigation following a second FDA Complete Response Letter for its OLC NDA, causing a stock price decline.
Importance 100.0 Sentiment -60.0
govactor
United States — Food and Drug Administration
The FDA issued a second Complete Response Letter for Unicycive's OLC NDA, citing manufacturing deficiencies, which triggered the stock decline and investigation.
Importance 80.0 Sentiment 0.0
priv
Block & Leviton
Block & Leviton is conducting the investigation into Unicycive Therapeutics for potential securities law violations, seeking to recover losses for investors.
Importance 50.0 Sentiment 10.0
govactor
United States — United States Securities and Exchange Commission
The SEC is mentioned as a potential recipient of whistleblower reports related to the investigation, but is not directly involved in the event.
Importance 20.0 Sentiment 0.0
exch
Nasdaq
Unicycive Therapeutics is listed on Nasdaq under the ticker UNCY; the stock price decline occurred on this exchange.
Importance 10.0 Sentiment 0.0
Relationships
Unicycive Therapeutics related ↔ United States — Food and Drug Administration
United States — Food and Drug Administration related ↔ United States — United States Securities and Exchange Commission
Block & Leviton related ↔ United States — United States Securities and Exchange Commission
United States — United States Securities and Exchange Commission related ↔ Nasdaq
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.